European Council for
Cardiovascular Research

Covid-19 and cardiovascular and metabolic disease

Fried et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164.

Guo J et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1.

Hill et al. Commentary: COVID-19 in Patients with Diabetes. Metabolism. 2020 Mar 24:154217. doi: 10.1016/j.metabol.2020.154217.

Gup et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. doi: 10.1001/jamacardio.2020.1017.

Huang et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.

Elkind et al. Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation. 2020 Mar 17. doi: 10.1161/CIRCULATIONAHA.120.046749.

Zhou et al. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism. 2020 Mar 24;107:154216. doi: 10.1016/j.metabol.2020.154216.

South et al. COVID-19, ACE2 and the Cardiovascular Consequences. Am J Physiol Heart Circ Physiol. 2020 Mar 31. doi: 10.1152/ajpheart.00217.2020.